To verify the glioneuronal architecture, we first stained BRAFV600E/AktDD brain slices with antibodies against the glial fibrillary acidic protein (GFAP) and microtubule-associated protein 2 (MAP2) and found a strong immunoreactivity for both markers within the tumor area (Fig. 1d). This evidence concerns the gene MAP2 and neoplasm.